Report
NASH: The Battle Has Started
• NASH is an attractive space. It is estimated that 1.5% to 6% of the population is affected by NASH (NonAlcoholic SteatoHepatitis) which, in the US alone, represents about 13 million people. Since there no treatment has been approved yet, the economic burden of NASH is significant, with direct and indirect costs of up to c.EUR24,000/patient/year. With over 55 drugs in development, several biotech and pharma companies are racing to address this untapped market worth c.USD15bn.
Provider
Bryan Garnier
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Jean-Jacques Le Fur
Other Reports from Bryan Garnier
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.